本学看護学部における3年次OSCEの実施と今後の課題

本報告は、2013年4月に開設した当看護学部において、2015年8月に3年生に対して初めて行ったOSCE (客観的臨床能力試験)の準備から実施までの総括である。一連の記録やマニュアル等から経過を振り返り、今後の改善点を検討した結果、学生の基礎技術の習熟に資する自主練習環境の整備、模擬患者の効果的な導入、評価者役や模擬患者役として実習病院や近隣機関の関係者が教育に参加できるような協力関係の構築が課題として示された

在来種ネズミモチと移入種トウネズミモチ(モクセイ科) の保全遺伝学的研究

Genetic introgression from introduced, non-native species into native populations is a growing challenge for biological conservation, and one that raises unique practical and ethical issues. Ligustrum lucidum is native to China, and cultivated or used in gardens in various areas in Japan. Recently, some studies reported that this species escaped from cultivated areas and was sympatric with L. japonicum. This indicates that L. japonicum faces the ecological and genetic risk of hybridization and introgression with non-native L. lucidum. Therefore, we examined whether hybridization between L. japonicum and the non-native L. lucidum has occurred in a coexisting population using phenological and molecular analyses. The phenological results indicate that there is very little overlap in the flowering times of the two species. Moreover, molecular analyses using PCR-RFLP of chloroplast and nuclear DNA sequences could not detect any hybridization or introgression of L. lucidum and L. japonicum in the population.移入種から在来種への遺伝子移入は生物学的保全のための懸念課題であり，実用的かつ倫理的な問題を提起している。中国原産のトウネズミモチ（Ligustrum lucidum）は日本の広い地域で園芸として栽植されているが逸出により分布を拡大しており，在来種のネズミモチ（L. japonicum）と同所的に生育していることが近年報告されている。このため，ネズミモチはトウネズミモチとの雑種形成や浸透交雑の生態学的リスクにさらされていると考えられる。そこで本研究では，在来種のネズミモチと移入種のトウネズミモチの間での雑種形成による遺伝的攪乱の有無を明らかにすることを目的として，開花期調査および分子遺伝学的調査を行った。開花期の調査結果より，両種の開花期がずれていることが明らかとなった。PCR-RFLP解析の結果，ネズミモチとトウネズミモチの間に交雑個体および浸透交雑個体を検出することはできなかったため，両種間での交雑は起こっていないと考えられる

Post-intervention Status in Patients With Refractory Myasthenia Gravis Treated With Eculizumab During REGAIN and Its Open-Label Extension

OBJECTIVE: To evaluate whether eculizumab helps patients with anti-acetylcholine receptor-positive (AChR+) refractory generalized myasthenia gravis (gMG) achieve the Myasthenia Gravis Foundation of America (MGFA) post-intervention status of minimal manifestations (MM), we assessed patients' status throughout REGAIN (Safety and Efficacy of Eculizumab in AChR+ Refractory Generalized Myasthenia Gravis) and its open-label extension. METHODS: Patients who completed the REGAIN randomized controlled trial and continued into the open-label extension were included in this tertiary endpoint analysis. Patients were assessed for the MGFA post-intervention status of improved, unchanged, worse, MM, and pharmacologic remission at defined time points during REGAIN and through week 130 of the open-label study. RESULTS: A total of 117 patients completed REGAIN and continued into the open-label study (eculizumab/eculizumab: 56; placebo/eculizumab: 61). At week 26 of REGAIN, more eculizumab-treated patients than placebo-treated patients achieved a status of improved (60.7% vs 41.7%) or MM (25.0% vs 13.3%; common OR: 2.3; 95% CI: 1.1-4.5). After 130 weeks of eculizumab treatment, 88.0% of patients achieved improved status and 57.3% of patients achieved MM status. The safety profile of eculizumab was consistent with its known profile and no new safety signals were detected. CONCLUSION: Eculizumab led to rapid and sustained achievement of MM in patients with AChR+ refractory gMG. These findings support the use of eculizumab in this previously difficult-to-treat patient population. CLINICALTRIALSGOV IDENTIFIER: REGAIN, NCT01997229; REGAIN open-label extension, NCT02301624. CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that, after 26 weeks of eculizumab treatment, 25.0% of adults with AChR+ refractory gMG achieved MM, compared with 13.3% who received placebo

Minimal Symptom Expression' in Patients With Acetylcholine Receptor Antibody-Positive Refractory Generalized Myasthenia Gravis Treated With Eculizumab

The efficacy and tolerability of eculizumab were assessed in REGAIN, a 26-week, phase 3, randomized, double-blind, placebo-controlled study in anti-acetylcholine receptor antibody-positive (AChR+) refractory generalized myasthenia gravis (gMG), and its open-label extension

La génistéine réprime l’induction des bourgeons prostatiques par la testostérone

Nous avons étudié l’induction des bourgeons prostatiques dans le sinus urogénital d’embryons de Rat cultivé en présence de testostérone et de génistéine, un inhibiteur de l’activité du récepteur du facteur de croissance de l’épiderme (EGF). Il a été observé que la génistéine peut exercer son action inhibitrice sur la prolifération des cellules de l’épithélium du sinus et l’induction des bourgeons prostatiques provoquées par la testostérone. Les résultats confirment notre hypothèse que les facteurs de croissance tels que l’EGF, sécrétés par le mésenchyme du sinus activé par la testostérone, provoquent la formation de bourgeons prostatiques dans le sinus fœtal